Q-omics provides the consensus-scored PRELID1P2 profile across patient tissues and cancer cell-line models. PRELID1P2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, PRELID1P2 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, PRELID1P2 RNA expression shows 5,673 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight ESCA, and KIRC as cancer lineages where PRELID1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRELID1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRELID1P2 survival associations across molecular data types. PRELID1P2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRELID1P2 RNA expression–survival associations across cancer types. High PRELID1P2 expression shows unfavorable associations in ESCA, UCS, LUSC, KIRP and LIHC, but favorable associations in KIRC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify ESCA as the clearest survival context for PRELID1P2 RNA expression.
This table summarizes PRELID1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRELID1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRELID1P2 shows higher tumor expression in KIRC. The KIRC box plot shows higher PRELID1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.227, t-test p < 0.001).
This table shows molecular features associated with PRELID1P2 in patient tissues and cancer cell lines. In patient samples, PRELID1P2 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
